PL2215075T3 - Pochodne chinolinonu jako inhibitory PARP - Google Patents
Pochodne chinolinonu jako inhibitory PARPInfo
- Publication number
- PL2215075T3 PL2215075T3 PL08841176T PL08841176T PL2215075T3 PL 2215075 T3 PL2215075 T3 PL 2215075T3 PL 08841176 T PL08841176 T PL 08841176T PL 08841176 T PL08841176 T PL 08841176T PL 2215075 T3 PL2215075 T3 PL 2215075T3
- Authority
- PL
- Poland
- Prior art keywords
- parp inhibitors
- quinolinone derivatives
- quinolinone
- derivatives
- parp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07119417 | 2007-10-26 | ||
| EP08841176.4A EP2215075B1 (en) | 2007-10-26 | 2008-10-22 | Quinolinone derivatives as parp inhibitors |
| PCT/EP2008/064243 WO2009053373A1 (en) | 2007-10-26 | 2008-10-22 | Quinolinone derivatives as parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2215075T3 true PL2215075T3 (pl) | 2014-04-30 |
Family
ID=39345428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08841176T PL2215075T3 (pl) | 2007-10-26 | 2008-10-22 | Pochodne chinolinonu jako inhibitory PARP |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8404713B2 (enExample) |
| EP (1) | EP2215075B1 (enExample) |
| JP (1) | JP5525447B2 (enExample) |
| ES (1) | ES2448870T3 (enExample) |
| PL (1) | PL2215075T3 (enExample) |
| WO (1) | WO2009053373A1 (enExample) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| WO2013169964A1 (en) * | 2012-05-09 | 2013-11-14 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| US9719970B2 (en) | 2012-11-30 | 2017-08-01 | Waters Technologies Corporation | Methods and apparatus for the analysis of vitamin D metabolites |
| JP6064062B2 (ja) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Ａｍｐｋを活性化させるインダゾール化合物 |
| MX381417B (es) | 2014-08-28 | 2025-03-12 | Asceneuron Sa | Inhibidores de glucosidasa. |
| PT3312177T (pt) * | 2015-06-09 | 2021-05-17 | Onconic Therapeutics Inc | Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| JP6971999B2 (ja) | 2016-02-25 | 2021-11-24 | エースニューロン・ソシエテ・アノニム | ピペラジン誘導体の酸付加塩 |
| JP2019506430A (ja) | 2016-02-25 | 2019-03-07 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
| CN108884077A (zh) | 2016-02-25 | 2018-11-23 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| AU2017400271B2 (en) | 2017-02-24 | 2020-09-24 | Asceneuron S.A. | Sulfoximine glycosidase inhibitors |
| US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
| US11458140B2 (en) | 2017-08-24 | 2022-10-04 | Asceneuron Sa | Annulated glycosidase inhibitors |
| WO2020039029A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Spiro compounds as glycosidase inhibitors |
| US11795165B2 (en) | 2018-08-22 | 2023-10-24 | Asceneuron Sa | Tetrahydro-benzoazepine glycosidase inhibitors |
| US12016852B2 (en) | 2018-08-22 | 2024-06-25 | Asceneuron Sa | Pyrrolidine glycosidase inhibitors |
| CA3110032A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S.A. | Succinate and fumarate acid addition salts of piperazine derivatives |
| US20220143042A1 (en) | 2019-02-22 | 2022-05-12 | Asceneuron Sa | Fused glycosidase inhibitors |
| TWI837403B (zh) * | 2019-07-19 | 2024-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| EP4003358B1 (en) | 2019-07-26 | 2025-12-31 | Health Research, Inc. | TREATMENT OF P53 DEFICIENCY CANCERS |
| US11795158B2 (en) | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| CN116783181B (zh) * | 2021-04-12 | 2026-01-30 | 上海瑛派药业有限公司 | 取代的稠合双环类化合物作为parp抑制剂及其应用 |
| TW202309025A (zh) | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| WO2022222921A1 (zh) * | 2021-04-22 | 2022-10-27 | 微境生物医药科技(上海)有限公司 | 含哌嗪结构的parp抑制剂、其制备方法及医药用途 |
| CN116867783B (zh) * | 2021-04-23 | 2026-08-07 | 康百达（四川）生物医药科技有限公司 | 吡啶衍生物及其在医药上的应用 |
| CN116601148A (zh) * | 2021-04-23 | 2023-08-15 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| TW202304911A (zh) * | 2021-04-23 | 2023-02-01 | 大陸商南京明德新藥研發有限公司 | 吡啶醯胺類化合物 |
| CN116710433B (zh) * | 2021-04-23 | 2026-05-05 | 康百达（四川）生物医药科技有限公司 | 一种选择性parp1抑制剂及其应用 |
| CN117321051A (zh) * | 2021-04-26 | 2023-12-29 | 重庆复尚源创医药技术有限公司 | 作为parp抑制剂的化合物 |
| AU2022280845A1 (en) | 2021-05-24 | 2023-12-14 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing heterocyclic compound, preparation method therefor, and application thereof in medicines |
| CN115403595A (zh) * | 2021-05-27 | 2022-11-29 | 江苏恒瑞医药股份有限公司 | 含氮杂环类化合物、其制备方法及其在医药上的应用 |
| WO2023036285A1 (zh) * | 2021-09-09 | 2023-03-16 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
| WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046149A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| WO2023051812A1 (zh) * | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 含氮杂环衍生物parp抑制剂及其用途 |
| WO2023051807A1 (zh) * | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 双环衍生物parp抑制剂及其用途 |
| WO2023051716A1 (zh) * | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 杂芳基衍生物parp抑制剂及其用途 |
| TWI876212B (zh) * | 2021-10-01 | 2025-03-11 | 美商辛瑟拉股份有限公司 | 吖丁啶及吡咯啶parp1抑制劑及其用途 |
| US20250222116A1 (en) * | 2021-10-22 | 2025-07-10 | Xizang Haisco Pharmaceutical Co., Ltd. | Parp-1 degradation agent and use thereof |
| CA3238572A1 (en) * | 2021-11-19 | 2023-05-25 | Jing Zhang | Selective parp1 inhibitor and application thereof |
| CN118382624A (zh) * | 2021-12-17 | 2024-07-23 | 凯复(苏州)生物医药有限公司 | Parp抑制剂、包含其的药物组合物及其用途 |
| CN118434725B (zh) * | 2022-01-20 | 2026-01-02 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
| CN120081844A (zh) | 2022-01-21 | 2025-06-03 | 新特拉有限公司 | Parp1抑制剂及其用途 |
| CA3246093A1 (en) * | 2022-01-27 | 2023-08-03 | Xinthera, Inc. | PARP1 INHIBITORS AND THEIR USES |
| AU2023212785A1 (en) * | 2022-01-28 | 2024-08-15 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| PT4497438T (pt) | 2022-04-28 | 2025-10-31 | Xinthera Inc C/O Gilead Sciences Inc | Inibidores tricíclicos da parp1 e suas utilizações |
| WO2023207284A1 (en) * | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Piperazine derivatives as parp1 inhibitiors |
| EP4514795A4 (en) * | 2022-04-28 | 2025-12-31 | Ningbo Newbay Tech Development Co Ltd | COMPOUNDS USED AS PARP1 INHIBITORS |
| AU2023275808A1 (en) * | 2022-05-25 | 2024-12-12 | Xizang Haisco Pharmaceutical Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| US20250346573A1 (en) * | 2022-06-02 | 2025-11-13 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Azaquinolinone derivative, preparation method therefor and use thereof |
| WO2024041608A1 (zh) * | 2022-08-24 | 2024-02-29 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂的晶体形式及其用途 |
| CN119677736A (zh) * | 2022-08-24 | 2025-03-21 | 四川海思科制药有限公司 | 一种杂芳基衍生物parp抑制剂药学上可接受的盐及其用途 |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| WO2024083201A1 (zh) * | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 并杂环类化合物及其用途 |
| WO2024083218A1 (zh) * | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 取代四氢吡啶类化合物及其用途 |
| KR20250103773A (ko) | 2022-11-23 | 2025-07-07 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 질소 함유 헤테로시클릭계 화합물의 약학적으로 사용 가능한 염, 결정형 및 제조 방법 |
| AU2023412594A1 (en) * | 2022-12-23 | 2025-07-10 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Parp1 inhibitors |
| CN117903159A (zh) * | 2022-12-30 | 2024-04-19 | 成都硕德药业有限公司 | 一种内酰胺类衍生物、其制备方法及用途 |
| WO2025101892A1 (en) * | 2023-11-10 | 2025-05-15 | Astellas Engineered Small Molecules US, Incorporated | Poly-adp ribose polymerase (parp) inhibitors and uses thereof |
| CN120040415A (zh) * | 2023-11-24 | 2025-05-27 | 中国药科大学 | 一种含喹啉酮骨架的化合物及其应用 |
| WO2025168048A1 (zh) * | 2024-02-08 | 2025-08-14 | 上海璎黎药业有限公司 | 一种三键结构化合物、其药物组合物及其应用 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB732581A (en) | 1952-01-18 | 1955-06-29 | Ciba Ltd | Manufacture of hydrazine compounds |
| DE1006423B (de) | 1952-01-18 | 1957-04-18 | Ciba Geigy | Verfahren zur Herstellung von Hydrazinophthalazinen |
| US3274194A (en) * | 1963-03-29 | 1966-09-20 | Miles Lab | Quinazolinedione derivatives |
| GB1062357A (en) | 1965-03-23 | 1967-03-22 | Pfizer & Co C | Quinazolone derivatives |
| GB1293565A (en) * | 1969-05-03 | 1972-10-18 | Aspro Nicholas Ltd | Aminophthalazines and pharmaceutical compositions thereof |
| US3919425A (en) * | 1971-04-09 | 1975-11-11 | Miles Lab | Method of producing vasodilation using certain 3-substituted-quinazoline derivatives |
| BE792206A (enExample) | 1971-12-02 | 1973-06-01 | Byk Gulden Lomberg Chem Fab | |
| FR2436781A1 (fr) | 1978-09-19 | 1980-04-18 | Berri Balzac | Derives d'amino-3 (1h,3h) quinazolinedione-2,4, leur procede de preparation et leurs applications en therapeutique |
| US4335127A (en) * | 1979-01-08 | 1982-06-15 | Janssen Pharmaceutica, N.V. | Piperidinylalkyl quinazoline compounds, composition and method of use |
| JPS5976082A (ja) | 1982-10-23 | 1984-04-28 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
| JPS60120872A (ja) | 1983-12-01 | 1985-06-28 | Kyowa Hakko Kogyo Co Ltd | 新規なヘテロ環状化合物及び強心剤 |
| US5001125A (en) | 1984-03-26 | 1991-03-19 | Janssen Pharmaceutica N.V. | Anti-virally active pyridazinamines |
| MA20387A1 (fr) | 1984-03-26 | 1985-10-01 | Janssen Pharmaceutica Nv | Pyridazinamines utiles comme agents anti-viraux et procede pour leur preparation |
| DK623586A (da) | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
| US5231184A (en) * | 1987-11-23 | 1993-07-27 | Janssen Pharmaceutica N.V. | Pridazinamine derivatives |
| US5177075A (en) * | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| CA2002864C (en) | 1988-11-29 | 1999-11-16 | Eddy J. E. Freyne | (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives |
| GB8827822D0 (en) * | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
| US5374637A (en) * | 1989-03-22 | 1994-12-20 | Janssen Pharmaceutica N.V. | N-(3-hydroxy-4-piperidinyl)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives |
| EP0391462A1 (en) | 1989-04-05 | 1990-10-10 | Janssen Pharmaceutica N.V. | Synergistic compositions containing ketanserin |
| US5160727A (en) | 1990-02-13 | 1992-11-03 | Warner-Lambert Company | Tumor cell sensitization method using quinazolinedione derivatives |
| IE913473A1 (en) * | 1990-10-15 | 1992-04-22 | Fujisawa Pharmaceutical Co | Quinazoline derivatives and their preparation |
| JP3333878B2 (ja) | 1992-04-23 | 2002-10-15 | メレルダウファーマスーティカルズ インコーポレイテッド | セロトニン５ｈｔ２拮抗剤としての４‐イミドメチル‐１‐［２’フェニル‐２’オキソエチル‐］ピペリジン類，それらの製法及び治療用途 |
| TW294595B (enExample) | 1992-11-20 | 1997-01-01 | Janssen Pharmaceutica Nv | |
| CA2118117A1 (en) | 1993-02-18 | 1994-08-19 | Shigeki Fujiwara | Adenosine uptake inhibitor |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| TW445263B (en) | 1996-02-29 | 2001-07-11 | Janssen Pharmaceutica Nv | Novel esters of 1,4-disubstituted piperidine derivatives |
| JPH107572A (ja) | 1996-06-17 | 1998-01-13 | Sumitomo Pharmaceut Co Ltd | 腫瘍壊死因子産生阻害剤 |
| DE59711622D1 (de) | 1996-09-10 | 2004-06-17 | Boehringer Ingelheim Pharma | Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| EP0999208A4 (en) * | 1997-05-30 | 2001-08-08 | Meiji Seika Kaisha | NITROGEN-BASED HETEROCYCLIC COMPOUNDS AND MEDICINES FOR TREATING HYPERLIPEMIA THAT CONTAIN THEM |
| JPH10330377A (ja) | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
| US6635642B1 (en) * | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
| US20020022636A1 (en) * | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| US6407116B1 (en) | 1997-09-16 | 2002-06-18 | Takeda Chemical Industries, Inc. | Nitrogenous fused-ring compounds, process for the preparation of the same, and drugs |
| US6133277A (en) | 1997-12-05 | 2000-10-17 | Janssen Pharmaceutica N.V. | (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties |
| JP2000191659A (ja) | 1999-01-04 | 2000-07-11 | Sumitomo Pharmaceut Co Ltd | 腫瘍壊死因子産生阻害剤 |
| EP1147112B1 (en) | 1999-01-29 | 2003-10-29 | Abbott Laboratories | Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands |
| US7265115B2 (en) * | 1999-01-29 | 2007-09-04 | Abbott Laboratories | Diazabicyclic CNS active agents |
| US6566372B1 (en) * | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| CN1703403A (zh) * | 2000-10-02 | 2005-11-30 | 詹森药业有限公司 | 趋代谢的谷氨酸盐受体拮抗剂 |
| ITMI20002358A1 (it) | 2000-10-31 | 2002-05-01 | Flavio Moroni | Derivati di tieno ,2, 3-c|isochinolin-3-one come inibitori della poli(a dp-ribosio)polimerasi |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| JP2002284699A (ja) | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
| US20040176361A1 (en) * | 2001-05-23 | 2004-09-09 | Masakazu Fujio | Fused heterocyclic compound and medicinal use thereof |
| KR100957516B1 (ko) | 2001-08-15 | 2010-05-14 | 이코스 코포레이션 | 2ｈ-프탈라진-1-온 및 이것의 사용 방법 |
| CA2465491A1 (en) | 2001-11-07 | 2003-05-15 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| AUPR975601A0 (en) | 2001-12-24 | 2002-01-31 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivatives |
| US6822097B1 (en) * | 2002-02-07 | 2004-11-23 | Amgen, Inc. | Compounds and methods of uses |
| AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| NZ535438A (en) | 2002-03-29 | 2006-08-31 | Janssen Pharmaceutica Nv | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
| US7119111B2 (en) | 2002-05-29 | 2006-10-10 | Amgen, Inc. | 2-oxo-1,3,4-trihydroquinazolinyl derivatives and methods of use |
| ATE540928T1 (de) * | 2002-11-22 | 2012-01-15 | Mitsubishi Tanabe Pharma Corp | Isochinolinverbindungen und ihre medizinische verwendung |
| US20050075364A1 (en) | 2003-07-01 | 2005-04-07 | Kap-Sun Yeung | Indole, azaindole and related heterocyclic N-substituted piperazine derivatives |
| NZ546991A (en) | 2003-11-20 | 2010-01-29 | Janssen Pharmaceutica Nv | 6-Alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as PARP inhibitors |
| NZ546990A (en) * | 2003-11-20 | 2010-03-26 | Janssen Pharmaceutica Nv | 7-Phenylalkyl substituted 2-quinolinones and 2 quinoxalinones as poly(adp-ribose) polymerase inhibitors |
| PT1689715E (pt) | 2003-12-03 | 2011-05-16 | Ym Biosciences Australia Pty | Inibidores da tubulina |
| JP4806353B2 (ja) * | 2003-12-05 | 2011-11-02 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ポリ（ａｄｐ−リボース）ポリメラーゼインヒビターとしての６−置換２−キノリノンおよび２−キノキサリノン |
| ES2565581T3 (es) | 2003-12-10 | 2016-04-05 | Janssen Pharmaceutica Nv | 2-Quinolinonas/2-quinoxalinonas 6-(hetero)ciclohexilalquil sustituidas como inhibidores de poli(ADP-ribosa) polimerasa |
| PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| WO2005117876A1 (en) | 2004-06-01 | 2005-12-15 | University Of Virginia Patent Foundation | Dual small molecule inhibitors of cancer and angiogenesis |
| WO2006003147A1 (en) | 2004-06-30 | 2006-01-12 | Janssen Pharmaceutica N.V. | Phthalazine derivatives as parp inhibitors |
| CA2568835C (en) | 2004-06-30 | 2014-05-27 | Janssen Pharmaceutica N.V. | Quinazolinone derivatives as parp inhibitors |
| JP5100376B2 (ja) * | 2004-06-30 | 2012-12-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐ阻害剤としてのキナゾリンジオン誘導体 |
| NZ560712A (en) | 2005-02-17 | 2010-12-24 | Synta Pharmaceuticals Corp | (3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders |
| CN101166732B (zh) * | 2005-04-28 | 2013-04-17 | 田边三菱制药株式会社 | 氰基吡啶衍生物及其作为药物的应用 |
| CN101316592A (zh) | 2005-08-24 | 2008-12-03 | 伊诺泰克制药公司 | 茚并异喹啉酮类似物及其用法 |
| CA2640678C (en) | 2006-02-03 | 2015-03-31 | Bionomics Limited | Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors |
| EP2468748B1 (en) | 2006-02-15 | 2016-05-25 | AbbVie Inc. | Pyrazoloquinolones are potent parp inhibitors |
| US8466150B2 (en) * | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| JP5545955B2 (ja) | 2007-03-08 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐおよびｔａｎｋ阻害剤としてのキノリノン誘導体 |
| US8153633B2 (en) * | 2007-06-25 | 2012-04-10 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
-
2008
- 2008-10-22 WO PCT/EP2008/064243 patent/WO2009053373A1/en not_active Ceased
- 2008-10-22 US US12/681,790 patent/US8404713B2/en active Active
- 2008-10-22 ES ES08841176.4T patent/ES2448870T3/es active Active
- 2008-10-22 EP EP08841176.4A patent/EP2215075B1/en active Active
- 2008-10-22 JP JP2010530433A patent/JP5525447B2/ja not_active Expired - Fee Related
- 2008-10-22 PL PL08841176T patent/PL2215075T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2215075B1 (en) | 2013-12-11 |
| WO2009053373A1 (en) | 2009-04-30 |
| US20100222348A1 (en) | 2010-09-02 |
| JP5525447B2 (ja) | 2014-06-18 |
| JP2011500758A (ja) | 2011-01-06 |
| EP2215075A1 (en) | 2010-08-11 |
| ES2448870T3 (es) | 2014-03-17 |
| US8404713B2 (en) | 2013-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201002466B (en) | Pyridazinone derivatives as parp inhibitors | |
| IL208103A0 (en) | Quinoline derivatives as axl kinase inhibitors | |
| IL193265A0 (en) | Quinoline derivatives | |
| EP2194044A4 (en) | Quinolone derivative | |
| IL202018A0 (en) | Quinoline derivatives as pi3 kinase inhibitors | |
| IL200656A0 (en) | Quinoline derivatives as fungicides | |
| ZA201005166B (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| ZA201006475B (en) | Heterocyclic derivatives | |
| IL193272A0 (en) | Pyrazoloquinolones are potent parp inhibitors | |
| IL212755A0 (en) | Pyrazinopyrazines and derivatives as kinase inhibitors | |
| IL212842A0 (en) | Azaindole derivatives as kinase inhibitors | |
| ZA201007317B (en) | Tertiary amine derivatives as phosphodiesterase-4 inhibitors | |
| ZA201005382B (en) | Substituted heteroarylamide diazepinopyrimidone derivatives | |
| IL196000A0 (en) | 2-arylindole derivatives as npges-i inhibitors | |
| IL208626A0 (en) | Imidazolidinone derivatives as 11b-hsd1 inhibitors | |
| IL207191A0 (en) | Substituted heteroaylamide oxazepyrimidone derivatives | |
| ZA200906423B (en) | Pyrazolone derivatives as PDE4 inhibitors | |
| IL206949A0 (en) | 2-aminoquinoline derivatives | |
| EP2344472A4 (en) | ISOCHINOLINONDERIVATE | |
| GB0818365D0 (en) | Quinoline compounds | |
| GB0714941D0 (en) | Inhibitors | |
| ZA200806877B (en) | Quinoline Derivatives | |
| GB0713152D0 (en) | Phosphodlesterase inhibitors | |
| HK1158642A (en) | Isoquinolinone derivatives | |
| GB0621107D0 (en) | Inhibitors of phosphodiesterase-4 |